NCT00429312View on ClinicalTrials.gov

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

December 31, 2009

Conditions
Melanoma
Interventions
BIOLOGICAL

JX-594

Thymidine kinase-deleted vaccinia virus plus GM-CSF

Trial Locations (3)

29605

Cancer Center of the Carolinas, Greenville

59101

Billings Clinic, Billings

90095

UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Jennerex Biotherapeutics

INDUSTRY

NCT00429312 - A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | Biotech Hunter | Biotech Hunter